10 completed, 5 recruiting, 3 terminated, 1 active not recruiting. 10 Phase 2, 6 Phase 1, 3 Phase 3, 2 Not applicable.
Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer Best Practice, Interview, Supportive Care - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | City of Hope Medical Center | 126 | 2026-09-09 | 2026-10-16 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary | Phase 1 / Phase 2 | Recruiting | Volastra Therapeutics, Inc. | 200 | 2023-10-18 | 2025-11-04 |
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | Australia New Zealand Gynaecological Oncology Group | 13 | 2023-05-22 | 2026-08-06 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Carboplatin, Ifosfamide, Paclitaxel - Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma | Phase 3 | Unknown | GOG Foundation | 637 | 2009-08-17 | 2021-09-30 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Avastin, Paclitaxel, Cisplatin - Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Completed | University of Oklahoma | 20 | 2007-07-01 | 2017-07-02 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-09-01 | 2015-12-07 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Adjuvant Therapy, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Infectious Disorder | Phase 1 | Completed | Gynecologic Oncology Group | 43 | 2006-06-01 | 2014-12-31 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2019-07-22 |
Ovarian Neoplasms (14) · Fallopian Tube Neoplasms (11) · Brenner Tumor (4) · Endometrial Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Bone Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinosarcoma (1) · Chromosomal Instability (1) · Communicable Diseases (1) · Dysgerminoma (1) · Giant Cell Tumor of Bone (1) · Histiocytoma, Malignant Fibrous (1)
Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Genital Diseases (17) · Genital Diseases, Female (17) · Genital Neoplasms, Female (17) · Neoplasms by Site (17) · Urogenital Diseases (17) · Urogenital Neoplasms (17) · Adnexal Diseases (16) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Gonadal Disorders (16) · Neoplasms (16) · Ovarian Diseases (16) · Fallopian Tube Diseases (11)
Bevacizumab (8) · Paclitaxel (7) · Disulfides (6) · Immunoglobulin G (6) · Taxes (6) · Carboplatin (4) · Cisplatin (2) · Practice Guidelines as Topic (2) · Specimen Handling (2) · Standard of Care (2) · olaparib (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1)
National Cancer Institute (NCI) (4) · Gynecologic Oncology Group (2) · Mayo Clinic (2) · ARCAGY/ GINECO GROUP (1) · Australia New Zealand Gynaecological Oncology Group (1) · City of Hope Medical Center (1) · GOG Foundation (1) · Imperial College London (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1) · Roswell Park Cancer Institute (1) · University of Oklahoma (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1) · Volastra Therapeutics, Inc. (1)
United States (17) · Canada (3) · United Kingdom (2) · Australia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Spain (1)
Amir A Jazaeri (1) · Amit Oza (1) · Amy Tiersten (1) · Anne Reb (1) · Clare Scott, AM MB BS PhD (1) · D. Scott McMeekin, MD (1) · Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Henry Pitot (1) · Joan Walker (1) · Jonathan Krell (1) · Katherine M Bell-McGuinn (1) · Kathryn Pennington (1) · Lisa Hess (1) · Marta Crispens, MD (1)
PMID 25318437, PMID 25488966, PMID 31708167, PMID 33610319, PMID 34986897, PMID 35007153, PMID 35382842, PMID 37702588
U10CA027469 (4), U10CA180868 (3), N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1)